Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Charlet

Neurology Houma, LA Medical Doctor

NPI 1023082856 CMS profile 46112

1022 Belanger St, Houma, LA 70360

Open in the dashboard

General payments

$38,855

524 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Charlet of Houma, LA is reported in the CMS Open Payments database as having received $38,855 across 524 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $194 9
2024 General $324 19
2023 General $1,100 57
2022 General $869 72
2021 General $27,407 136
2020 General $1,283 75
2019 General $7,679 156

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Charlet
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Michael Charlet were reported at $194. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Michael Charlet Neurology median Middle half National median
2019 $7,679 $474 $118–$2,177 $163
2020 $1,283 $367 $82–$2,309 $114
2021 $27,407 $438 $104–$2,547 $132
2022 $869 $442 $103–$2,388 $149
2023 $1,100 $464 $119–$2,312 $160
2024 $324 $468 $119–$2,323 $164
2025 $194 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biohaven Pharmaceuticals, Inc. $26,300 64 payments
  2. Novartis Pharmaceuticals Corporation $5,054 22 payments
  3. AbbVie, Inc. $982 67 payments
  4. Sunovion Pharmaceuticals Inc. $538 33 payments
  5. Allergan Inc. $535 36 payments
  6. Genzyme Corporation $494 24 payments
  7. Amgen Inc. $395 19 payments
  8. UCB, Inc. $368 25 payments
  9. Alexion Pharmaceuticals, Inc. $362 8 payments
  10. Teva Pharmaceuticals USA, Inc. $211 15 payments
  11. Other $3,615 211 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $24,571 17 payments
  2. Food and Beverage $8,651 488 payments
  3. Consulting Fee $3,667 1 payment
  4. Travel and Lodging $1,955 17 payments
  5. Education $11 1 payment
Products named General payments · program years 2019–2025
  1. NURTEC ODT $26,470 91 payments
  2. AIMOVIG $5,222 32 payments
  3. APTIOM $562 39 payments
  4. QULIPTA $380 29 payments
  5. Soliris $362 8 payments
  6. Briviact $340 21 payments
  7. UBRELVY $336 19 payments
  8. BOTOX Hyperhydrosis $303 21 payments
  9. BOTOX Botox Therapeutic $283 16 payments
  10. BOTOX Neuroscience $221 16 payments
  11. Other $5,046 277 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$16,714

Medicare's payments for the services billed

Medicare patients

76

Average age 71

Services billed

296

42 women, 34 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 29%
Diabetes 25%
Osteoporosis 24%
Depression 22%
Chronic kidney disease 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $87
$87 — —
QULIPTA
  • AbbVie, Inc. $82
$82 — —
UBRELVY
  • AbbVie, Inc. $26
$26 — —
NURTEC ODT
  • PFIZER INC. $21
$21 — —
ZAVZPRET
  • PFIZER INC. $21
$21 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

524 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record